1-methyl-4-[3-(2-trifluoromethyl-thioxanthen-9-ylidene)-propyl]-piperazine | 2252-14-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻喃类
• 英文名称: 1-methyl-4-[3-(2-trifluoromethyl-thioxanthen-9-ylidene)-propyl]-piperazine
• 英文别名: 1-Methyl-4-[3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazine
• CAS: 2252-14-4
• 化学式: C₂₂H₂₃F₃N₂S
• 分子量: 404.499
• InChiKey: CBPGGEXQESURPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  31.8
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• THIOXANTHENE DERIVATES USEFULTO TREAT INFECTIOUS DISEASES
  申请人：BKG Pharma ApS

  公开号：EP2114406A1

  公开（公告）日：2009-11-11
• THIOXANTHENE DERIVATES AS SOLE ANTI-INFECTIVE AGENTS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES
  申请人：BKG Pharma ApS

  公开号：EP2114406B1

  公开（公告）日：2011-05-25
• THIOXANTHENE DERIVATES USEFUL TO TREAT INFECTIOUS DISEASES
  申请人：Giwercman Birgit Kjældgaard

  公开号：US20100113430A1

  公开（公告）日：2010-05-06

  The present invention is directed to certain thioxanthene derivatives and phenothiazine derivatives suitable for use as anti-infective agents, in particular, for treatment of infectious diseases. The invention furthermore relates to compositions comprising said anti-infective agents.
• [EN] THIOXANTHENE DERIVATES USEFULTO TREAT INFECTIOUS DISEASES<br/>[FR] DÉRIVÉS DE THIOXANTHÈNE UTILES POUR TRAITER LES MALADIES INFECTIEUSES
  申请人：BKG PHARMA APS

  公开号：WO2008080408A1

  公开（公告）日：2008-07-10

  [EN] The present invention is directed to certain thioxanthene derivatives and phenothiazine derivatives suitable for use as anti-infective agents, in particular, for treatment of infec- tious diseases. The invention furthermore relates to compositions comprising said anti- infective agents.
  [FR] La présente invention concerne certains dérivés de thioxanthène et certains dérivés de phénothiazine qui peuvent être utilisés en tant qu'agents anti-infectieux, notamment pour le traitement de maladies infectieuses. L'invention concerne également des compositions comprenant lesdits agents anti-infectieux.